Table 4. Canonical pathways associated with the top 999 predictors able to separate respiratory chemical sensitizers from non-respiratory sensitizers.
| Canonical Pathway | -log(p-value) | Regulated molecules 1 |
|---|---|---|
| Oxidative phosphorylation | 17.62 | ATP5E, ATP5I, ATPK, COX Vb, COX VIIa-2, NDUFA1, NDUFA13, NDUFA2, NDUFA3, NDUFA6, NDUFA7, NDUFA9, NDUFAB1, NDUFB10,NDUFB4, NDUFB6, NDUFB8, NDUFB9, NDUFC1, NDUFS4, NDUFS5, NDUFS6, NDUFS8, NDUFV2, UQCR10, UQCRQPC |
| Ubiquinone metabolism | 13.29 | NDUFA1, NDUFA13, NDUFA2, NDUFA3, NDUFA6, NDUFA7, NDUFA9, NDUFAB1, NDUFB10, NDUFB4, NDUFB6, NDUFB8, NDUFB9, NDUFC1, NDUFS4, NDUFS5, NDUFS6, NDUFS8, NDUFV2 |
| Granzyme B signaling | 4.72 | Bid, Caspase-2, Lamin A/C,LAMP2,Smac/Diablo, tBid, Tubulin alpha |
| FAS signaling cascades | 3.79 | Bid, c-FLIP (S), Caspase-2, DAXX, Lamin A/C, Smac/Diablo, tBid |
| Cytoplasmic/mitochondrial transport of proapoptotic proteins Bid, Bmf and Bim | 3.57 | Bid, DAXX, DLC1 (Dynein LC8a), DLC2 (Dynein LC8b), Smac/Diablo, tBid |
| Inhibitory PD-1 signaling in T cells | 3.27 | BCL2L1, CD8, CD8 alpha, CD80, CD86, MHC class II, PTEN |
| HSP60 and HSP70/ TLR signaling pathway | 3.22 | CD80, CD86, MD-2, MEK1/2, MHC class II, MyD88, Ubiquitin |
| Astrocyte differentiation from adult stem cells | 3.17 | HES1, ID1, ID2, ID3, MEK1/2, SOX1 |
| Apoptotic TNF-family pathways | 3.06 | Apo-2L(TNFSF10), BCL2L1, Bid, Caspase-2, Smac/Diablo, tBid |
| TNFR1 signaling pathway | 3.00 | Bid, c-FLIP (S), Caspase-2, jBid, Smac/Diablo, tBid |
| Role of Nek in cell cycle regulation | 2.80 | Histone H1, Ran, Tubulin (in microtubules), Tubulin alpha, Tubulin beta |
| ATP/ITP metabolism | 2.70 | 5'-NTC, ADSL, APRT, POLR2G, POLR2J, PPAP, RPB10, RPB6, RPB8, RRP41 |
| Generation of memory CD4+ T cells | 2.51 | BCL2L1, CD80, CD86, IL7RA, MHC class II |
| Dynein-dynactin motor complex in axonal transport in neurons | 2.48 | DYNLL, DYNLT, Tctex-1, TMEM108, Tubulin (in microtubules), Ubiquitin |
| Antigen presentation by MHC class II | 2.44 | HLA-DM, HLA-DRA1, MHC class II |
| IL-33 signaling pathway | 2.36 | Histone H2A, Histone H2B, MEK1/2, MyD88, ST2L, Ubiquitin |
| Insulin regulation of translation | 2.27 | eEF2, eIF4A, eIF4B, eIF4G1/3, MEK1(MAP2K1) |
| TNF-alpha-induced Caspase-8 signaling | 2.23 | Bid, c-FLIP (S), Caspase-2, PP2A regulatory, tBid |
| Antigen presentation by MHC class I | 2.18 | CD8,CD8 alpha, PSMB5, PSME3 |
| Main pathways of Schwann cells transformation in neurofibromatosis type 1 | 2.18 | BCL2L1, Calmodulin, MEK1(MAP2K1), MEK1/2, Neuregulin 1,PTEN |
| Granzyme A signaling | 2.08 | Histone H1, Histone H2B, Lamin A/C, LAMP2 |
| G-CSF-induced myeloid differentiation | 2.08 | G-CSF receptor, MEK1/2, Myeloblastin, PERM |
| Substance P mediated membrane blebbing | 2.07 | MRLC, Tubulin (in microtubules), Tubulin alpha |
| Role of IAP-proteins in apoptosis | 2.03 | Bid, Smac/Diablo, tBid, Ubiquitin |
1Molecules indicated in bold are present in GRPS.